Back to products

Abevmy 400 mg Injection

Brand Name: Abevmy 400

Molecule: Bevacizumab

Strength: 400 mg

Quantity: 1 Vial

Form: Injection

Packaging Type: Single-use Vial

Manufacturer/Marketed By: Mylan

Country of Origin: India

Description

Abevmy 400 mg Vial contains Bevacizumab, an anti-cancer monoclonal antibody used to treat various advanced solid tumors. It works by restricting blood supply to cancer cells, helping slow tumor growth. Administered under oncologist supervision.

Benefits

Slows tumor growth and spread
Enhances effectiveness of chemotherapy
Improves progression-free survival in eligible patients
Effective across multiple cancer types
Well-established targeted biologic therapy

Indications and Usage

Abevmy 400 mg Vial is indicated for:

Metastatic colorectal cancer
Non-small cell lung cancer (NSCLC)
Ovarian, fallopian tube & peritoneal cancer
Glioblastoma
Renal cell carcinoma
Cervical cancer

Treatment must be prescribed and supervised by an oncologist and administered in a medical facility.

How it Works

Bevacizumab targets and blocks Vascular Endothelial Growth Factor (VEGF) — a protein responsible for forming new blood vessels. By inhibiting VEGF, it reduces blood supply to tumors, slowing cancer growth and progression.

Dosage & Administration

Dose is based on body weight and cancer type
Given as an intravenous infusion in a hospital or infusion center
Typically administered every 2 or 3 weeks
Monitor blood pressure, kidney function, and treatment response regularly
Do not self-administer

Side Effects

Common side effects:

High blood pressure
Fatigue
Headache
Diarrhea or constipation
Nosebleeds
Protein in urine

Serious side effects (seek medical attention):

Severe bleeding
Blood clots
Gastrointestinal perforation
Poor wound healing
Kidney damage
Heart complications

Warning and Precaution

Not recommended during pregnancy or breastfeeding
Avoid treatment around major surgery due to impaired wound healing risk
Monitor for hypertension, bleeding, and proteinuria
Inform doctor about blood thinners or existing heart disease
Report abdominal pain, severe headache, chest pain, or unusual bleeding immediately
Not suitable for patients with uncontrolled hypertension or active bleeding

Ruxolitinib Tablets Receive FDA Approval for Hematologic Malignancies

The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another

May 18, 2026

Tovorafenib Approved in Europe for Children with BRAF-Altered Low-Grade Glioma

n Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 14, 2026.n n This marks an important

May 14, 2026

FDA Approves Vepdegestrant for ER+/HER2–, ESR1-Mutated Breast Cancer: A New Targeted Option

Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 6, 2026. Breast cancer treatment continues to evolve

May 6, 2026

Product	Manufacturer / Marketed By	Price
Bevatas 400 mg Injection	Intas Pharma	Ask for Price
Avastin 400 mg Injection	Roche	Ask for Price
Cizumab 400 mg Vial	Hetero Healthcare	Ask for Price